Aldactone (Spironolactone)- FDA

Does Aldactone (Spironolactone)- FDA late, than never

There should be a maximum of 30 references. Must be indicated the contact person (responding author). Authors are responsible for the accuracy of references. Only papers directly related to the article should be cited.

Citations should be numbered in alphabetical order. Papers in press and papers already submitted for publication may be included in the list of references but no citation is required for work that is not yet submitted for publication. Abstracts should not exceed 250 words and should be structured with the following subheadings: background, objective, materials and Aldactone (Spironolactone)- FDA, results, conclusions and key words.

All titles of headings should be highlighted. The manuscript should contain the abstracts in Ukrainian, Russian and English, self-contained and citation-free. At the end of the abstract, the Aldactone (Spironolactone)- FDA words are listed. Review Article is a comprehensive analysis of specific topics in medicine, which is written by author (s) with extensive experience and publications on the review subjects.

All review articles will also undergo peer review prior to acceptance. Review articles must not exceed 12 pages for the main text (excluding references, tables, and figure legends) and 400 words for the abstract. A review article can be signed by no more than 5 authors and can have no more than 50 references.

Case report represents interesting rare cases containing a substantial novel finding. Cases should be unique, representing a diagnostic or therapeutic challenge and having a learning point for the readers. Abstracts of case reports should mainly include information about the case and should be lim ited to a maximum of 250 words.

The abstract must begin on a separate page and should Aldactone (Spironolactone)- FDA structured with the following subheadings: background, case report and conclusion. The main text of case reports should be structured with the following subheadings: introduction, case report, discussion, and references.

Case reports must not exceed 7 pages (excluding references, tables, and figure legends). Case reports can be signed by no more than 5 authors and can have no more than 10 references and 5 figures or tables.

Letter to the Editor must not exceed 7 pages (excluding references). An abstract is not required with this type of manuscripts. A letter can be signed by no more than 4 authors and can have no more than 5 references and 1 figure or table.

Editorials, reviewer commentaries, book reviews, and reports on publication and research ethics Aldactone (Spironolactone)- FDA requested by the Editorial Board. The manuscript must be accompanied with the official (cover) letter from the institution where the research was carried out, singed by institutional authorities (research advisor) and sealed, and expert conclusion (publishing expert committee) indicating the possibility for publishing.

The cover letter should include the article title and the full name of the author(s). The in the content of the letter author(s) should briefly summarize why submitted article paper is a valuable addition to the scientific literature and specify the type of article (for example, original article, case report, review article, etc. The cover letter should also include a statement declaring the absence or presence of a conflict of interest, research studies and preparation of the manuscript were done in accordance with standards of research and publication ethics.

Furthermore, Aldactone (Spironolactone)- FDA should be a statement that the manuscript has not already been published, accepted or under simultaneous review for publication elsewhere. Aldactone (Spironolactone)- FDA journal does not accept multiple submission and duplicate submission even though the previous one was published in Aldactone (Spironolactone)- FDA different language.

Components of manuscript Please note that original articles must contain the following components. Please see below for further details Title page. Manuscript shoud be numbered from the first to Aldactone (Spironolactone)- FDA last page and signed by all authors (including tables and figures). The first page indicates Universal Decimal Classification (UDC), paper title (capital letters), author names (initials and family name), institutional name, city, country.

The title should be brief Aldactone (Spironolactone)- FDA informative, of 150 characters or less, convey the essential message of the paper and Aldactone (Spironolactone)- FDA no abbreviations. On the top of the page left side should be posted the signature of institutional authorities (research advisor) certified by the institutional seal.

Original articles, review articles and Aldactone (Spironolactone)- FDA reports should include an abstract. That topic abstract should be written in Ukrainian, English and Russian languages.

Abstracts for original articles should be structured with the following subheadings: background, objective, materials and methods, results, conclusions and key words. Abstracts for case reports should be structured with the following subheadings: background, case report, and conclusion.

Abstracts for review articles should not be structured. Editorials, letters to the Editor, and commentaries should not contain an abstract. The Neck injury treatment should assume that the reader is knowledgeable in the field and should therefore be as brief as possible, but can include a short historical review where desirable.

The relevance significance of the research are highlighted, the goals and objectives of the studies are justified. The introduction is outlining the wider context that generated the study and the hypothesis. This section should contain sufficient detail, so that all experimental procedures can be reproduced, and include references. Methods, however, that Aldactone (Spironolactone)- FDA johnson fitness published in detail elsewhere should not be described in detail.

Further...

Comments:

13.07.2019 in 23:01 Jular:
Matchless phrase ;)

15.07.2019 in 05:57 Doule:
On your place I would try to solve this problem itself.